Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is a Healthcare company (Biotechnology) with a market capitalization of $224M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Eledon Pharmaceuticals, Inc. had a Maz Rating of 2.69 out of 5 (C+, Hold), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.35), above most of its sector; its weakest was Growth (1.35), among the weakest in its sector. The other factors: Valuation 3.18 (valued in line with its sector); Financial Health 2.86 (around the middle of its sector); Profitability 1.47 (among the weakest in its sector). The current rating is for members: log in to see it.
At $2.76, Eledon Pharmaceuticals, Inc. trades at 4.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -136.4%, return on invested capital of -73.8% and a free cash flow yield of -33.4%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 7.90. Over the past 52 weeks the share price ranged from $1.35 to $4.49, with a beta of 0.85.
Eledon Pharmaceuticals, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.